Biogen Inc. (NASDAQ:BIIB) Q3 2024 Earnings Call Transcript October 30, 2024 8:30 AM ET

Company Participants

Stephen Amato - Senior Director of IR
Chris Viehbacher - President and CEO
Priya Singhal - Head of Development
Mike McDonnell - CFO
Alisha Alaimo - Head & President of North America

Conference Call Participants

Brian Abrahams - RBC Capital Markets
Phil Nadeau - TD Cowen
Marc Goodman - Leerink
Salveen Richter - Goldman Sachs
Michael Yee - Jefferies
Umer Raffat - Evercore ISI
Jay Olson - Oppenheimer
Evan Seigerman - BMO Capital Markets
Paul Matteis - Stifel
Terence Flynn - Morgan Stanley

Operator

Good morning. My name is Cynthia, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2024 Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be question-and-answer session. [Operator Instructions] Today's conference is being recorded. Thank you. I would now like to turn the conference over to Dr. Stephen Amato, Senior Director of Investor Relations. Dr. Amato, you may begin your conference.

Stephen Amato

Thank you. Good morning, and welcome to Biogen's third quarter 2024 earnings call. During this call, we'll make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results as well as reconciliations between GAAP and non-GAAP results discussed on this call can be found in the Investors section of biogen.com. We have also posted the slides on our website that will be used during this call.

On today's call, I'm joined by our President and Chief Executive Officer, Chris Viehbacher, Dr. Priya Singhal, Head of Development; Mike McDonnell, Chief Financial Officer; as well as our Head and President of North America, Alisha Alaimo who will be available for Q&A. We will make some opening comments, and then we'll move to the Q&A session. To allow us to get through as many questions as possible, we kindly ask that you limit yourself to one question.

I will now turn the call over to Chris.

Chris Viehbacher

Thank you, Steve. Good morning, everyone. I'll start first by thanking you, Steve for stepping up as Interim Head of IR and done a great job of preparing us for this quarter. Also earlier this week, we announced the retirement plans of our CFO, Mike McDonnell, and also the appointment of his successor, Robin Kramer. But Mike is still very firmly in the saddle as CFO, and we will be recognizing his significant contribution to Biogen with the fourth quarter earnings call later.